3.91
0.00 (0.00%)
| Penutupan Terdahulu | 3.91 |
| Buka | 3.96 |
| Jumlah Dagangan | 10,630 |
| Purata Dagangan (3B) | 34,926 |
| Modal Pasaran | 41,696,492 |
| Harga / Jualan (P/S) | 294.07 |
| Harga / Buku (P/B) | 29.88 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Aug 2025 - 8 Aug 2025 |
| Margin Operasi (TTM) | -37,468.63% |
| EPS Cair (TTM) | 3.38 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -51.70% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -19.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 26.43% |
| Nisbah Semasa (MRQ) | 2.45 |
| Aliran Tunai Operasi (OCF TTM) | -19.88 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -11.33 M |
| Pulangan Atas Aset (ROA TTM) | -135.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -485.36% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Serina Therapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | 3.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -1.40 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 63.85% |
| % Dimiliki oleh Institusi | 3.37% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Broadwood Capital Inc | 30 Sep 2025 | 83,195 |
| Waverly Advisors, Llc | 30 Sep 2025 | 67,492 |
| Linscomb Wealth, Inc. | 30 Sep 2025 | 18,800 |
| Keel Point, Llc | 30 Jun 2025 | 17,774 |
| Piscataqua Savings Bank | 30 Sep 2025 | 28 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MOREADITH RANDALL | - | 3.74 | -13,000 | -48,444 |
| Jumlah Keseluruhan Kuantiti Bersih | -13,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -48,444 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 3.74 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MOREADITH RANDALL | Pegawai | 03 Dec 2025 | Jual (-) | 5,000 | 3.48 | 17,400 |
| MOREADITH RANDALL | Pegawai | 03 Dec 2025 | Pelaksanaan pilihan | 5,000 | - | - |
| MOREADITH RANDALL | Pegawai | 02 Dec 2025 | Jual (-) | 1,500 | 3.81 | 5,715 |
| MOREADITH RANDALL | Pegawai | 02 Dec 2025 | Pelaksanaan pilihan | 1,500 | - | - |
| MOREADITH RANDALL | Pegawai | 25 Nov 2025 | Jual (-) | 5,965 | 3.91 | 23,323 |
| MOREADITH RANDALL | Pegawai | 25 Nov 2025 | Pelaksanaan pilihan | 5,965 | - | - |
| MOREADITH RANDALL | Pegawai | 24 Nov 2025 | Jual (-) | 535 | 3.75 | 2,006 |
| MOREADITH RANDALL | Pegawai | 24 Nov 2025 | Pelaksanaan pilihan | 535 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 13 Nov 2025 | Pengumuman | Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights |
| 03 Nov 2025 | Pengumuman | Serina Therapeutics Provides Regulatory Update on SER-252 Program |
| 08 Oct 2025 | Pengumuman | Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors |
| 06 Oct 2025 | Pengumuman | Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson’s Disease |
| 09 Sep 2025 | Pengumuman | Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson’s Disease |
| 08 Sep 2025 | Pengumuman | Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |